Exagamglogene autotemcel 4million-13million cells/ml dispersion for infusion vials
NHS hospitals in England used £23,114,000 of indicative cost of Exagamglogene autotemcel 4million-13million cells/ml dispersion for infusion vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 0.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Exagamglogene autotemcel 4million-13million cells/ml dispersion for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Exagamglogene autotemcel 4million-13million cells/ml dispersion for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Manchester University Nhs Ft | £9,906,000 |
| Imperial College Healthcare Nhs Trust | £4,953,000 |
| University College London Foundation Tr | £3,302,000 |
| Birmingham Womans & Childrens Nhs Ft | £3,302,000 |
| King's College Hpl Nhs Foundation Trust | £1,651,000 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.